More than 1 in 10 people worldwide are living with CKD.(1)
Up to 2 of 3 cases are caused by diabetes and high blood pressure.(2)
2-3% of the annual healthcare budget is spent on end-stage kidney disease treatment in high-income countries.(3)
Mortality due to CKD is increasing; rising from 0.9 to 1.2 million between 2005 and 2015.(4)
AstraZeneca has so far chosen to add the first novel AI-generated CKD target to enter their drug portfolio. We expect this will not be the last, and moving forward, we will continue to identify new targets with an embedded precision medicine strategy, using omics and clinical data to best understand how to treat different patient subgroups.
(1) Kidney Care UK. An estimated 1 in 10 people worldwide have chronic kidney disease. Available from: https://www.kidneycareuk.org/news-and-campaigns/news/estimated-1-10-people-worldwide-have-chronic-kidney-disease/ [Accessed January 2021].
(2) National Kidney Foundation. Kidney Disease: The Basics. Available from: https://www.kidney.org/news/newsroom/factsheets/KidneyDiseaseBasics. [Accessed January 2021].
(3) WHO. Global burden of kidney disease. Available at: https://www.who.int/bulletin/volumes/96/6/17-206441/en/ [Accessed January 2021].
(4) Wang H, et al. Lancet 2016; 288:1459544 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31012-1/fulltext